Most Read Articles
Stephen Padilla, Yesterday
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
01 Aug 2020
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

Paromomycin may halt SARS-CoV-2 cell entry, replication

11 Jul 2020

The aminoglycoside antibiotic paromomycin effectively targets not one but two of SARS-CoV-2's weak points—spike protein and main protease, according to a study. In effect, this could stop the virus from getting into a cell and from replicating.

Researchers applied an in-silico approach to examine the potential of multiple antimalarial (n=15) and FDA-approved (n=2,413) drugs to act against both SARS-CoV-2 main protease and receptor binding domain (RBD) portion of the spike protein. They used molecular docking analysis and then run a molecular dynamics simulation to estimate the binding and stability of the complexes.

None of the antimalarial drugs showed strong binding affinity with active sites of either protease or RBD.

Among the FDA-approved drugs, acarbose, colistin, and paromomycin showed the strongest activity against the protease domain, with glide scores of –13.139, –12.63, and –11.579, respectively. On the other hand, framycitin, acarbose, and paromomycin had the highest binding affinity for the RBD, with glide scores of –11.233, –10.49, and –10.01, respectively.

A broad-spectrum aminoglycoside antimicrobial originally used to treat acute and chronic intestinal infections, paromomycin could be tested to reposition its therapeutic target for treating COVID-19, the researchers said. In addition, the glucose-lowering acarbose, which also showed strong binding affinity for both target proteins, could be tested at clinical levels on diabetic patients with the infectious disease.

The dual-target approach applied in this study is more advantageous than a single target, which has been explored in previous investigations, according to the researchers. It is because the approach may keep the virus from entering host cells and halt viral replication at the same time.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, Yesterday
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
01 Aug 2020
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.